Literature DB >> 9797250

Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and moraxella catarrhalis by MIC determination and time-kill assay.

G A Pankuch1, D B Hoellman, G Lin, S Bajaksouzian, M R Jacobs, P C Appelbaum.   

Abstract

The microdilution MICs of HMR 3647, erythromycin A, azithromycin, clarithromycin, roxithromycin, and pristinamycin against 50/90% of 249 Haemophilus influenzae and 50 Moraxella catarrhalis isolates were 2/4, 0.06/0.125; 8/16, 0.25/0.25; 2/4, 0.06/0.125; 16/16, 0.25/0.25; 32/>32, 1/2; and 2/4, 0.5/0.5 microg/ml. Azithromycin was bactericidal against all 10 H. influenzae and 3 of 5 M. catarrhalis isolates and HMR 3647, erythromycin A, clarithromycin, roxithromycin, and pristinamycin were bacteriostatic, against all 15 strains after 24 h at the MIC.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9797250      PMCID： PMC105990     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Susceptibility testing of Haemophilus influenzae--an international collaborative study in quality assessment.

Authors:  S F Yeo; E Akalin; S Arikan; R Auckenthaler; T Bergan; K Dornbusch; A J Howard; W Hryniewicz; R N Jones; G Koupari; N J Legakis; J McLaughlin; C Ozkuyumcu; A Percival; I Phillips; D Reeves; R Spencer; R E Warren; J D Williams
Journal:  J Antimicrob Chemother       Date:  1996-09       Impact factor: 5.790

2.  Antipneumococcal activities of RP 59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies.

Authors:  G A Pankuch; C Lichtenberger; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

Review 3.  Haemophilus influenzae: antibiotic susceptibility.

Authors:  C A Needham
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

4.  Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

5.  Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents.

Authors:  G A Pankuch; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

6.  Bacteriostatic and bactericidal activity of azithromycin against Haemophilus influenzae.

Authors:  F W Goldstein; M F Emirian; A Coutrot; J F Acar
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

7.  Antibiotic susceptibility patterns of community-acquired respiratory isolates of Moraxella catarrhalis in western Europe and in the USA. The Alexander Project Collaborative Group.

Authors:  S L Berk; J H Kalbfleisch
Journal:  J Antimicrob Chemother       Date:  1996-07       Impact factor: 5.790

8.  In-vitro activity of clarithromycin combined with its 14-hydroxy metabolite A-62671 against Haemophilus influenzae.

Authors:  B Olsson-Liljequist; B M Hoffman
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

9.  The development of macrolides: clarithromycin in perspective.

Authors:  H C Neu
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

10.  Individual and combined activities of clarithromycin and its 14-hydroxy metabolite in a murine model of Haemophilus influenzae infection.

Authors:  E Vallée; E Azoulay-Dupuis; R Swanson; E Bergogne-Bérézin; J J Pocidalo
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790
View more
  11 in total

1.  In vivo efficacy of the new ketolide telithromycin (HMR 3647) in murine infection models.

Authors:  A Bonnefoy; M Guitton; C Delachaume; P Le Priol; A M Girard
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 2.  Review of macrolides and ketolides: focus on respiratory tract infections.

Authors:  G G Zhanel; M Dueck; D J Hoban; L M Vercaigne; J M Embil; A S Gin; J A Karlowsky
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.

Authors:  Tatiana Bogdanovich; Catherine Clark; Lois Ednie; Gengrong Lin; Kathy Smith; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.

Authors:  T A Davies; L M Kelly; D B Hoellman; L M Ednie; C L Clark; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

5.  Telithromycin.

Authors:  J A Balfour; D P Figgitt
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae.

Authors:  Klaudia Kosowska; Kim Credito; Glenn A Pankuch; Dianne Hoellman; Gengrong Lin; Catherine Clark; Bonifacio Dewasse; Pamela McGhee; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

7.  Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents.

Authors:  K L Credito; G Lin; G A Pankuch; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 8.  The ketolides: a critical review.

Authors:  George G Zhanel; Michael Walters; Ayman Noreddin; Lavern M Vercaigne; Aleksandra Wierzbowski; John M Embil; Alfred S Gin; Stephen Douthwaite; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  In vitro and in vivo properties of dihydrophthalazine antifolates, a novel family of antibacterial drugs.

Authors:  Patrick Caspers; Luc Bury; Bérangère Gaucher; Jutta Heim; Stuart Shapiro; Sibylle Siegrist; Anne Schmitt-Hoffmann; Laure Thenoz; Heinrich Urwyler
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

10.  Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study.

Authors:  Charles M Fogarty; Tushar C Patel; Lala M Dunbar; Bruno P Leroy
Journal:  BMC Infect Dis       Date:  2005-05-31       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.